Changes in HIV Incidence among People Who Inject Drugs in Taiwan following Introduction of a Harm Reduction Program: A Study of Two Cohorts


Background:
Harm reduction strategies for combating HIV epidemics among people who inject drugs (PWID) have been implemented in several countries. However, large-scale studies using sensitive measurements of HIV incidence and intervention exposures in defined cohorts are rare. The aim of this study was to determine the association between harm reduction programs and HIV incidence among PWID.

Methods and Findings:
The study included two populations. For 3,851 PWID who entered prison between 2004 and 2010 and tested HIV positive upon incarceration, we tested their sera using a BED HIV-1 capture enzyme immunoassay to estimate HIV incidence. Also, we enrolled in a prospective study a cohort of 4,357 individuals who were released from prison via an amnesty on July 16, 2007. We followed them with interviews at intervals of 6–12 mo and by linking several databases. A total of 2,473 participants who were HIV negative in January 2006 had interviews between then and 2010 to evaluate the association between use of harm reduction programs and HIV incidence. We used survival methods with attendance at methadone clinics as a time-varying covariate to measure the association with HIV incidence. We used a Poisson regression model and calculated the HIV incidence rate to evaluate the association between needle/syringe program use and HIV incidence. Among the population of PWID who were imprisoned, the implementation of comprehensive harm reduction programs and a lower mean community HIV viral load were associated with a reduced HIV incidence among PWID. The HIV incidence in this population of PWID decreased from 18.2% in 2005 to 0.3% in 2010. In an individual-level analysis of the amnesty cohort, attendance at methadone clinics was associated with a significantly lower HIV incidence (adjusted hazard ratio: 0.20, 95% CI: 0.06–0.67), and frequent users of needle/syringe program services had lower HIV incidence (0% in high NSP users, 0.5% in non NSP users). In addition, no HIV seroconversions were detected among prison inmates.

Conclusions:
Although our data are affected by participation bias, they strongly suggest that comprehensive harm- reduction services and free treatment were associated with reversal of a rapidly emerging epidemic of HIV among PWID.

Please see later in the article for the Editors' Summary


Vyšlo v časopise: Changes in HIV Incidence among People Who Inject Drugs in Taiwan following Introduction of a Harm Reduction Program: A Study of Two Cohorts. PLoS Med 11(4): e32767. doi:10.1371/journal.pmed.1001625
Kategorie: Research Article
prolekare.web.journal.doi_sk: 10.1371/journal.pmed.1001625

Souhrn

Background:
Harm reduction strategies for combating HIV epidemics among people who inject drugs (PWID) have been implemented in several countries. However, large-scale studies using sensitive measurements of HIV incidence and intervention exposures in defined cohorts are rare. The aim of this study was to determine the association between harm reduction programs and HIV incidence among PWID.

Methods and Findings:
The study included two populations. For 3,851 PWID who entered prison between 2004 and 2010 and tested HIV positive upon incarceration, we tested their sera using a BED HIV-1 capture enzyme immunoassay to estimate HIV incidence. Also, we enrolled in a prospective study a cohort of 4,357 individuals who were released from prison via an amnesty on July 16, 2007. We followed them with interviews at intervals of 6–12 mo and by linking several databases. A total of 2,473 participants who were HIV negative in January 2006 had interviews between then and 2010 to evaluate the association between use of harm reduction programs and HIV incidence. We used survival methods with attendance at methadone clinics as a time-varying covariate to measure the association with HIV incidence. We used a Poisson regression model and calculated the HIV incidence rate to evaluate the association between needle/syringe program use and HIV incidence. Among the population of PWID who were imprisoned, the implementation of comprehensive harm reduction programs and a lower mean community HIV viral load were associated with a reduced HIV incidence among PWID. The HIV incidence in this population of PWID decreased from 18.2% in 2005 to 0.3% in 2010. In an individual-level analysis of the amnesty cohort, attendance at methadone clinics was associated with a significantly lower HIV incidence (adjusted hazard ratio: 0.20, 95% CI: 0.06–0.67), and frequent users of needle/syringe program services had lower HIV incidence (0% in high NSP users, 0.5% in non NSP users). In addition, no HIV seroconversions were detected among prison inmates.

Conclusions:
Although our data are affected by participation bias, they strongly suggest that comprehensive harm- reduction services and free treatment were associated with reversal of a rapidly emerging epidemic of HIV among PWID.

Please see later in the article for the Editors' Summary


Zdroje

1. MathersBM, DegenhardtL, PhillipsB, WiessingL, HickmanM, et al. (2008) Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 372: 1733–1745.

2. World Health Organization, United Nations Office on Drugs and Crime, Joint United Nations Programme on HIV/AIDS (2012) WHO, UNODC, UNAIDS technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users: 2012 revision. Available: http://apps.who.int/iris/bitstream/10665/77969/1/9789241504379_eng.pdf. Accessed 1 January 2013.

3. MathersBM, DegenhardtL, AliH, WiessingL, HickmanM, et al. (2010) HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 375: 1014–1028.

4. StrathdeeSA, HallettTB, BobrovaN, RhodesT, BoothR, et al. (2010) HIV and risk environment for injecting drug users: the past, present, and future. Lancet 376: 268–284.

5. DegenhardtL, MathersB, VickermanP, RhodesT, LatkinC, et al. (2010) Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet 376: 285–301.

6. GowingL, FarrellMF, BornemannR, SullivanLE, AliR (2011) Oral substitution treatment of injecting opioid uses for prevention of HIV infection. Cochrane Database Syst Rev 2011: CD004145.

7. MacArthurGJ, MinozziS, MartinN, VickermanP, DerenS, et al. (2012) Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ 345: e5945.

8. BeyrerCB, Malinowska-SempruchK, KamarulzamanAK, KazatchkineM, SidibeM, et al. (2010) Time to act: a call for comprehensive responses to HIV in people who use drugs. Lancet 376: 551–563.

9. WiessingL, LikataviciusG, KlempovaD, HedrichD, NardoneA, et al. (2009) Associations between availability and coverage of HIV-prevention measures and subsequent incidence of diagnosed HIV infection among injection drug users. Am J Public Health 99: 1049–1052.

10. Van Den BergC, SmitC, Van BrusselG, CoutinhoR, PrinsM (2007) Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam cohort studies among drug users. Addiction 102: 1454–1462.

11. AlistarSS, OwensDK, BrandeauML (2011) Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine. PLoS Med 8: e1000423 doi:10.1371/journal.pmed.1000423

12. AceijasC, StimsonGV, HickmanM, RhodesT (2004) Global overview of injecting drug use and HIV infection among injecting drug users. AIDS 18: 2295–2303.

13. ChenYMA, KuoSHS (2007) HIV-1 in Taiwan. Lancet 369: 623–625.

14. HuangYF, KuoHS, Lew-TingCY, TianF, YangCH, et al. (2011) Mortality among a cohort of drug users after their release from prison: an evaluation of the effectiveness of a harm reduction program in Taiwan. Addiction 106: 1437–1445.

15. FangCT, HsuHM, TwuSJ, ChenMY, ChangYY, et al. (2004) Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis 190: 879–885.

16. LyuSY, SuLW, ChenYM (2011) Effects of education on harm-reduction programmes. Lancet 379: e28–e30.

17. HallHT, SongR, RhodesP, PrejeanJ, AnQ, et al. (2008) Estimation of HIV incidence in the United States. JAMA 300: 520–529.

18. UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance (2011) When and how to use assays for recent infection to estimate HIV incidence at a population level. Geneva: World Health Organization. Available: http://www.who.int/diagnostics_laboratory/hiv_incidence_may13_final.pdf. Accessed 1 July 2013.

19. Taiwan Ministry of Justice (2012) [Statistics of justice in 2010.] Available: http://www.moj.gov.tw/public/Attachment/13118133562.pdf. Accessed 30 September 2012.

20. Taiwan Centers for Disease Control Department of Health Executive Yuan (2012) [HIV/AIDS statistics.] Available: http://www.cdc.gov.tw/professional/info.aspx?treeid=BEAC9C103DF952C4&nowtreeid=2F13020F8A921CCB&tid=5250BA9AD485D6C3. Accessed 1 December 2012.

21. DobbsT, KennedyS, PauCP, McDougalJS, ParekhBS (2004) Performance characteristics of the immunoglobulin G-capture BED-enzyme immunoassay, an assay to detect recent human immunodeficiency virus type 1 seroconversion. J Clin Microbiol 42: 2623–2628.

22. McWalterTA, WelteA (2010) Relating recent infection prevalence to incidence with a sub-population of non-progressors. J Math Biol 60: 687–710.

23. ParekhBS, HansonDL, HargroveJ, BransonB, GreenT, DobbsT, et al. (2012) Determination of mean recency period for estimation of HIV type 1 incidence with the BED-capture EIA in persons infected with diverse subtypes. AIDS Res Hum Retroviruses 27: 265–273.

24. SuissaS (2008) Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 167: 492–499.

25. AgrestiA, CoullBA (1998) Approximate is better than “exact” for interval estimation of binomial proportions. Am Stat 52: 119–126.

26. WoodE, KerrT, MarshallBD, LiK, ZhangR, et al. (2009) Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ Wood E 338: b1649.

27. BarrioG, BravoMJ, BrugalMT, DiezM, RegidorE, et al. (2012) Harm reduction interventions for drug injectors or heroin users in Spain: expanding coverage as the storm abates. Addiction 107: 1111–1122.

28. WilliamsAB, McNellyEA, WilliamsAE, D'AquilaRT (1992) Methadone maintenance treatment and HIV type 1 seroconversion among injecting drug users. AIDS Care 4: 35–41.

29. MetzgerDS, WoodyGE, McLellanAT, O'BrienCP, DruleyP, et al. (1993) Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr 6: 1049–1056.

30. SerpelloniG, CarrieriMP, RezzaG, MorgantiS, GommaM, et al. (1994) Methadone treatment as a determinant of HIV risk reduction among injection drug users: a nested case-control study. AIDS Care 6: 215–220.

31. MossAR, VranizanK, GorterR, BacchettiP, WattersJ, et al. (1994) HIV seroconversion in intravenous drug users in San Francisco, 1985–1990. AIDS 8: 223–231.

32. WodakA, CooneyA (2006) Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. Subst Use Misuse 41: 777–813.

33. Tilson H, Aramrattana A, Bozzette S (2007) Preventing HIV infection among injecting drug users in high-risk countries: an assessment of the evidence. Washington (District of Columbia): Institute of Medicine.

34. PalmateerN, KimberJ, HickmanM, HutchinsonS, RhodesT, et al. (2010) Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. Addiction 105: 844–859.

35. TurnerKM, HutchinsonS, VickermanP, HopeV, CraineN, et al. (2011) The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction 106: 1978–1988.

36. MacArthurGJ, van VelzenE, PalmateerN, KimberJ, PharrisA, et al. (2014) Interventions to prevent HIV and hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. Int J Drug Policy 25: 34–52.

37. JürgensR, BallA, VersterA (2009) Interventions to reduce HIV transmission related to injecting drug use in prison. Lancet Infect Dis 9: 57–66.

38. TaylorA, MunroA, AllenE, DunleavyK, CameronS, et al. (2013) Low incidence of HCV amongst prisoners in Scotland. Addiction 108: 1296–1304.

39. IguchiMY, LondonJA, ForgeNG, HickmanL, FainT, et al. (2002) Elements of well-being affected by criminalizing the drug user. Public Health Rep 117: S146–S150.

Štítky
Interné lekárstvo

Článok vyšiel v časopise

PLOS Medicine


2014 Číslo 4

Najčítanejšie v tomto čísle
Kurzy

Zvýšte si kvalifikáciu online z pohodlia domova

Eozinofilní granulomatóza s polyangiitidou
nový kurz

Betablokátory a Ca antagonisté z jiného úhlu
Autori: prof. MUDr. Michal Vrablík, Ph.D., MUDr. Petr Janský

Autori: doc. MUDr. Petr Čáp, Ph.D.

Farmakoterapie akutní a chronické bolesti

Získaná hemofilie - Povědomí o nemoci a její diagnostika

Všetky kurzy
Prihlásenie
Zabudnuté heslo

Nemáte účet?  Registrujte sa

Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa